AI Earnings Predictions for Intuitive Surgical Inc. (ISRG)

EX-99.1

2 q226ex-991earningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Contact: Investor Relations (408) 523-2161

INTUITIVE ANNOUNCES SECOND QUARTER EARNINGS

SUNNYVALE, CALIF., July 16, 2026 – Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026.

Q2 Highlights

•Worldwide procedures (da Vinci and Ion combined) grew approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew approximately 15%, and Ion procedures grew approximately 36%.

•The Company placed 468 da Vinci surgical systems, compared with 395 in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems, compared with 180 in the second quarter of 2025. The Company placed 55 Ion endoluminal systems, compared with 54 in the second quarter of 2025.

•The Company grew its da Vinci surgical system installed base to 11,710 systems as of June 30, 2026, an increase of 12% compared with 10,488 as of June 30, 2025. The Company grew its Ion endoluminal system installed base to 1,096 systems as of June 30, 2026, an increase of 21% compared with 905 as of June 30, 2025.

•Second quarter 2026 revenue of $2.89 billion increased 19%, compared with $2.44 billion in the second quarter of 2025.

•Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025.

•Second quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, in the second quarter of 2025.

•Second quarter 2026 GAAP and non-GAAP* net income attributable to Intuitive Surgical, Inc. included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under the International Emergency Economic Powers Act (“IEEPA”).

•The Company repurchased 0.9 million shares of its common stock for $0.38 billion in the second quarter of 2026.

Q2 Financial Summary

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Second quarter 2026 revenue was $2.89 billion, an increase of 19% compared with $2.44 billion in the second quarter of 2025. The higher second quarter revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue, and an increase in the installed base of da Vinci and Ion systems.

Second quarter 2026 instruments and accessories revenue increased by 18% to $1.73 billion, compared with $1.47 billion in the second quarter of 2025. The increase in instruments and accessories revenue was primarily driven by approximately 15% growth in da Vinci procedure volume and approximately 36% growth in Ion procedure volume.

Second quarter 2026 systems revenue was $685 million, compared with $575 million in the second quarter of 2025. The higher systems revenue reflected a higher lease installed base, higher da Vinci system average selling prices, and increased da Vinci system placements compared with the second quarter of 2025. The Company placed 468 da Vinci surgical systems, of which 246 were da Vinci 5 systems, in the second quarter of 2026, compared with 395 systems, of which 180 were da Vinci 5 systems, in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 254 systems placed under operating lease arrangements, of which 131 systems were placed under usage-based operating lease arrangements, compared with 193 systems placed under operating lease arrangements, of which 124 systems were placed under usage-based operating lease arrangements in the second quarter of 2025.

Page 1 of 10

Second quarter 2026 GAAP income from operations increased to $972 million, compared with $743 million in the second quarter of 2025. Second quarter 2026 GAAP income from operations included share-based compensation expense of $213 million, compared with $200 million in the second quarter of 2025. Second quarter 2026 non-GAAP* income from operations increased to $1.22 billion, compared with $0.95 billion in the second quarter of 2025.

Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025. Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $17 million, or $0.05 per diluted share, compared with $33 million, or $0.09 per

EX-99.1

2 q126ex-991earningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Contact: Investor Relations (408) 523-2161

INTUITIVE ANNOUNCES FIRST QUARTER EARNINGS

SUNNYVALE, CALIF. April 21, 2026 – Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2026.

Q1 Highlights

•Worldwide procedures (da Vinci and Ion combined) grew approximately 17% compared with the first quarter of 2025. Da Vinci procedures grew approximately 16%, and Ion procedures grew approximately 39%.

•The Company placed 431 da Vinci surgical systems, compared with 367 in the first quarter of 2025. The first quarter 2026 da Vinci surgical system placements included 232 da Vinci 5 systems, compared with 147 in the first quarter of 2025. The Company placed 52 Ion endoluminal systems, compared with 49 in the first quarter of 2025.

•The Company grew its da Vinci surgical system installed base to 11,395 systems as of March 31, 2026, an increase of 12% compared with 10,189 as of March 31, 2025. The Company grew its Ion endoluminal system installed base to 1,041 systems as of March 31, 2026, an increase of 22% compared with 853 as of March 31, 2025.

•First quarter 2026 revenue of $2.77 billion increased 23%, compared with $2.25 billion in the first quarter of 2025.

•First quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $822 million, or $2.28 per diluted share, compared with $698 million, or $1.92 per diluted share, in the first quarter of 2025.

•First quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $901 million, or $2.50 per diluted share, compared with $662 million, or $1.81 per diluted share, in the first quarter of 2025.

•The Company repurchased 2.3 million shares of its common stock for $1.1 billion in the first quarter of 2026.

Q1 Financial Summary

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

First quarter 2026 revenue was $2.77 billion, an increase of 23% compared with $2.25 billion in the first quarter of 2025. The higher first quarter revenue was driven by growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of da Vinci and Ion systems.

First quarter 2026 instruments and accessories revenue increased by 23% to $1.69 billion, compared with $1.37 billion in the first quarter of 2025. The increase in instruments and accessories revenue was primarily driven by approximately 16% growth in da Vinci procedure volume, customer buying patterns, and approximately 39% growth in Ion procedure volume.

First quarter 2026 systems revenue was $651 million, compared with $523 million in the first quarter of 2025. The higher systems revenue reflected increased da Vinci system placements, a higher lease installed base, and higher da Vinci system average selling prices compared with the first quarter of 2025. The Company placed 431 da Vinci surgical systems, of which 232 were da Vinci 5 systems, in the first quarter of 2026, compared with 367 systems, of which 147 were da Vinci 5 systems, in the first quarter of 2025. The first quarter 2026 da Vinci surgical system placements included 243 systems placed under operating lease arrangements, of which 118 systems were placed under usage-based operating lease arrangements, compared with 198 systems placed under operating lease arrangements, of which 107 systems were placed under usage-based operating lease arrangements in the first quarter of 2025.

First quarter 2026 GAAP income from operations increased to $855 million, compared with $578 million in the first quarter of 2025. First quarter 2026 GAAP income from operations included share-based compensation expense of $213 million, compared with $190 million in the first quarter of 2025. First quarter 2026 non-GAAP* income from operations increased to $1.08 billion, compared with $0.77 billion in the first quarter of 2025.

Page 1 of 7

First quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $822 million, or $2.28 per diluted share, compared with $698 million, or $1.92 per diluted share, in the first quarter of 2025. First quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $73 million, or $0.20 per diluted share, compared with $145 million, or $0.40 per diluted share, in the first quarter of 2025.

First quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $901 million, or $2.50 per diluted share, compared with $662 million, or $1.81 per diluted share, in the first quarter of 2025.

The Company ended the first quarter

isrg-202601220001035267FALSE00010352672026-01-222026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026

INTUITIVE SURGICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-30713 77-0416458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

1020 Kifer Road Sunnyvale, California 94086 (Address of Principal Executive Offices) (zip code) Registrant’s telephone number, including area code: (408) 523-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.Results of Operations and Financial Condition.

On January 22, 2026, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01.Financial Statements and Exhibits.

d) Exhibits. Exhibit No.Description

99.1Press release issued by Intuitive Surgical, Inc., dated January 22, 2026

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTUITIVE SURGICAL, INC.

Date: January 22, 2026 By:/s/ JAMIE E. SAMATH Name: Jamie E. Samath

Title: Executive Vice President, Chief Financial Officer